[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • BACKGROUND: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients.
  • Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  • CONCLUSION: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


2. Benedetti-Panici P, Zullo MA, Plotti F, Manci N, Muzii L, Angioli R: Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy. Cancer; 2004 May 15;100(10):2110-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy.
  • BACKGROUND: The objective of the current study was to evaluate the incidence of long-term bladder dysfunction after type 3-4 radical hysterectomy in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy (NACT).
  • METHODS: A case-control study was conducted to evaluate the occurrence of long-term bladder dysfunction in 76 patients with International Federation of Gynecology and Obstetrics Stage IB-IIA (> 4 cm), Stage IIB, and Stage III cervical carcinoma who underwent type 3-4 radical hysterectomy after NACT.
  • The length of vagina removed was significantly greater among patients who had detrusor overactivity and mixed urinary incontinence compared with patients who had a normal diagnosis.
  • Among patients who underwent type 4 radical hysterectomy, the extent of caudal resection of rectovaginal ligaments and vaginal tissue was found to be more strongly associated with bladder dysfunction than was the extent of lateral parametrial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hysterectomy. Urinary Bladder / physiopathology. Uterine Cervical Neoplasms / physiopathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Time Factors. Urinary Incontinence, Stress / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139052.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Dasanu CA, Herzog TJ: Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med; 2009;11(1):6
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina and cervix were previously shown to be tumors occurring in female offspring exposed prenatally to diethylstilbestrol.
  • This report describes the first clinical case of clear cell adenocarcinoma of the ovary linked to early diethylstilbestrol exposure in utero.
  • She underwent surgery and staging that revealed clear cell adenocarcinoma confined to the left ovary.
  • Medical records established unequivocally that the patient's mother received diethylstilbestrol therapy throughout the pregnancy.
  • CONCLUSION: Our case is consistent with clear cell adenocarcinoma, probably related to diethylstilbestrol exposure in utero.
  • It reinforces the need for continued vigilance in individuals prenatally exposed to this drug.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Ovarian Neoplasms / chemically induced. Prenatal Exposure Delayed Effects / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1615-24 [7370920.001]
  • [Cites] Biol Reprod. 1983 Apr;28(3):735-44 [6850046.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] Obstet Gynecol. 2005 Jan;105(1):167-73 [15625159.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Semin Surg Oncol. 1990;6(6):343-6 [2263810.001]
  • (PMID = 19295927.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2654676
  •  go-up   go-down


Advertisement
4. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW: Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat; 2006;38(3):133-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after postoperative radiation therapy for endometrial carcinoma.
  • PURPOSE: We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).
  • MATERIALS AND METHODS: Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study.
  • Forty-one patients received total abdominal hysterectomy, 41 patients received Wertheim's operation and 1 underwent vaginal hysterectomy.
  • The histologic diagnoses were adenocarcinoma in seventy-four patients (89%).
  • A total dose of 7,500 approximately 9,540 cGy (median dose: 8511) was prescribed to the vaginal surface.
  • Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs).
  • Among the 29 stage III patients, 1 (3%) relapsed in the vagina.
  • Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.
  • Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):233-8 [11161865.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):79-85 [11006036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):101-4 [9747826.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):905-11 [1555983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):276-8 [3280811.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(4):519-28 [3685293.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):236-42 [12713986.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):274-80 [12468325.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):437-42 [11855884.001]
  • (PMID = 19771273.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741680
  • [Keywords] NOTNLM ; Endometrial neoplasms / Patterns of failure / Postoperative radiation therapy
  •  go-up   go-down


5. Patel H, Joseph JV, Amodeo A, Kothari K: Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy? J Minim Access Surg; 2009 Oct;5(4):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for total pelvic exenteration in a male (removal of the bladder, prostate and rectum) and in a woman (removal bladder, uterus, vagina, ovaries and rectum) are rare.
  • The advanced stage generally dictates that the patient has some form of chemotherapy or radiotherapy, or a combination of two to shrink/debulk the tumour.
  • We report the first two cases of a salvage laparoscopic total pelvic exenteration in a male for rectal adenocarcinoma invading into the bladder and prostate, post-chemo-radiotherapy and in a woman for squamous cell carcinoma of cervix invading the bladder and rectum post-chemo-radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):907-18 [1115180.001]
  • [Cites] Surg Clin North Am. 1969 Apr;49(2):431-47 [4886910.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1023-30 [16890276.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Surg Oncol Clin N Am. 2005 Apr;14(2):289-300 [15817240.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):161-7 [10504663.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):130-5 [8995561.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):207-10 [7896187.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):205-16 [3410348.001]
  • [Cites] Am J Obstet Gynecol. 1985 May 1;152(1):12-6 [2581447.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):934-43 [2586960.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):369-77 [14599868.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):311-5 [12217753.001]
  • [Cites] Semin Surg Oncol. 1999 Apr-May;16(3):236-41 [10225302.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):93-8 [2792911.001]
  • [Cites] Am J Obstet Gynecol. 1977 Dec 15;129(8):881-92 [930972.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):279-82 [2722049.001]
  • [Cites] Obstet Gynecol. 1989 Jun;73(6):1027-34 [2726106.001]
  • (PMID = 20407571.001).
  • [ISSN] 1998-3921
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2843126
  • [Keywords] NOTNLM ; Laparoscopy / malignancy / pelvic exenteration
  •  go-up   go-down


6. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • Brachytherapy also improves vaginal control.
  • Both treatments imply significant side effects that a fine RT technique can help avoiding.
  • Intensity Modulated RT (IMRT) enables the treatment of the target volume while protecting normal tissue.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Brachytherapy / methods. Female. Humans. Kidney / pathology. Middle Aged. Postoperative Period. Radiotherapy Planning, Computer-Assisted. Treatment Outcome. Vagina / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


7. Marttunen MB, Cacciatore B, Hietanen P, Pyrhönen S, Tiitinen A, Wahlström T, Ylikorkala O: Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer; 2001 Apr 6;84(7):897-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II-III breast cancer.
  • Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment.
  • In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment.
  • The mean (+/-SD) follow-up time was 2.3 +/- 0.8 years.
  • Vaginal dryness, which was present in 6.0% at baseline, increased during the use of tamoxifen (26.2%) and toremifene (24.1%).
  • One patient in the toremifene group developed endometrial adenocarcinoma at 12 months, and one patient had breast cancer metastasis on the endometrium.
  • In conclusion, tamoxifen and toremifene cause similarly vasomotor and vaginal symptoms.
  • Our data suggest that so close endometrial surveillance as used in our study may not be mandatory during the first 3 years of use of antioestrogen treatment.
  • [MeSH-major] Endometrium / drug effects. Estrogen Receptor Modulators / pharmacology. Postmenopause. Tamoxifen / pharmacology. Toremifene / pharmacology. Vagina / drug effects
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Prospective Studies. Vasomotor System / drug effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):447-51 [8116695.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):222-7 [8004590.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(1):27-39 [7981454.001]
  • [Cites] Lancet. 1995 Jan 28;345(8944):254-5 [7823732.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):443-7 [7835785.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2556-66 [7595707.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1292 [7475728.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):261-6 [7590484.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1327-34 [8623865.001]
  • [Cites] Curr Opin Obstet Gynecol. 1996 Feb;8(1):27-31 [8777254.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):297-9 [8688340.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):629-40 [8862888.001]
  • [Cites] Drugs. 1997 Jul;54(1):141-60 [9211086.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):821-7 [9427424.001]
  • [Cites] Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7 [9556787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jun;178(6):1145-50 [9662294.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 1):563-8 [9764629.001]
  • [Cites] Obstet Gynecol. 1999 Mar;93(3):363-6 [10074980.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):133-43 [10573106.001]
  • [Cites] Br J Cancer. 1988 Jun;57(6):601-3 [3044432.001]
  • [Cites] Drugs. 1989 Apr;37(4):451-90 [2661195.001]
  • [Cites] J Steroid Biochem. 1990 Jun 22;36(3):203-6 [2142233.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1842-7 [1888251.001]
  • [Cites] Clin Obstet Gynecol. 1992 Mar;35(1):28-39 [1544246.001]
  • [Cites] Fertil Steril. 1992 Nov;58(5):959-63 [1426382.001]
  • [Cites] Am J Obstet Gynecol. 1993 Feb;168(2):620-30 [8438940.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):660-4 [8469450.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):275-80 [8345555.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1850-5 [8230266.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):448-52 [7905955.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1318-21 [7910323.001]
  • (PMID = 11286468.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 7NFE54O27T / Toremifene
  • [Other-IDs] NLM/ PMC2363827
  •  go-up   go-down


8. Erşahin C, Huang M, Potkul RK, Hammadeh R, Salhadar A: Mesonephric adenocarcinoma of the vagina with a 3-year follow-up. Gynecol Oncol; 2005 Dec;99(3):757-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the vagina with a 3-year follow-up.
  • BACKGROUND: Mesonephric adenocarcinoma of the vagina is exceedingly rare, with only one well-documented case in the literature.
  • Little is known regarding clinical presentation, pathological characteristics, therapy, or prognosis of the vaginal mesonephric adenocarcinoma.
  • CASE: A 55-year-old woman presented with a polypoid mass at the right vaginal apex, extending to the right paravaginal tissue.
  • The tumor was an adenocarcinoma with ductal and tubular pattern arising in a background of mesonephric remnants.
  • The patient is disease-free 3 years after surgery, radiation therapy, and chemotherapy.
  • CONCLUSION: We report the second case of mesonephric adenocarcinoma of the vagina with metastasis to the right fallopian tube and to one paravaginal lymph node.
  • [MeSH-major] Adenocarcinoma / pathology. Mesonephroma / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137744.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Takemoto S, Ushijima K, Nakaso K, Fujiyoshi N, Kamura T: Primary adenocarcinoma of the vagina successfully treated with neoadjuvant chemotherapy consisting of paclitaxel and carboplatin. J Obstet Gynaecol Res; 2009 Jun;35(3):579-83
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the vagina successfully treated with neoadjuvant chemotherapy consisting of paclitaxel and carboplatin.
  • Primary vaginal adenocarcinoma unassociated with antenatal diethylstilbestrol (DES) exposure is extremely rare.
  • A 69-year-old woman presented with vaginal bleeding but no history of antenatal DES exposure.
  • She had a solid tumor in the recto-vaginal space, diagnosed as FIGO stage III vaginal adenocarcinoma.
  • After neoadjuvant chemotherapy consisting of paclitaxel and carboplatin, the tumor became undetectable.
  • Thereafter, radiotherapy was applied to the pelvis and vagina in order to reinforce the state of remission.
  • The present case was successfully treated with chemotherapy and radiotherapy, suggesting that chemotherapy may be an option for the treatment of this type of tumor.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carboplatin / administration & dosage. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Vaginal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527405.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Adewuyi SA, Shittu OS, Rafindadi AH, Zayyan MS, Samaila MO, Oguntayo AO: Cisplatin chemotherapy for haemostasis in bleeding cervical cancer: experience from a resource-poor setting. Niger Postgrad Med J; 2010 Jun;17(2):122-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin chemotherapy for haemostasis in bleeding cervical cancer: experience from a resource-poor setting.
  • BACKGROUND: Cervical cancer is the commonest cancer in northern Nigeria.
  • The number of patients requiring radiotherapy for various malignancies is beyond the available facilities and expertise leading to long waiting time and disease progression with its attendant sequelae.
  • This is the basis of using other orthodox treatment modalities as first line.
  • PATIENTS AND METHODS: Between January 2006 and December 2007, 116 patients with histologically confirmed cervical cancer with vaginal bleeding as the predominant symptom were treated.
  • Patients were interviewed with a structured pro forma on a 3-weekly basis during chemotherapy schedules to assess and evaluate per vaginal bleeding and discharge.
  • Dose of chemotherapy was 70 mg/m² every 3 weeks.
  • 62 patients were having per vagina bleeding for more than 6 months before commencement of chemotherapy (range 1-60 months).
  • 49 patients had blood transfusion before chemotherapy, average of 2.7 pints of blood transfused per patient.
  • Squamous cell carcinoma is the commonest histology type followed by adenocarcinoma with 95 and 16 patients respectively.
  • 81 patients had complete cessation of per vagina bleeding with 69 having complete cessation on or before 4th course of chemotherapy (9th week) and complete cessation of per vagina discharges was seen in 52 patients.
  • 115 patients had a performance status KPS of below 80 prior to chemotherapy, and after completing 6 cycles, 100 patients had KPS of 80 and above.
  • CONCLUSION: In resource-poor setting, Cisplatin based chemotherapy can be used by medical, gynaecological oncologists and general practitioners to control vaginal bleeding and improve the quality of life of patients pending radiotherapy.
  • For optimal treatment with chemoradiotherapy, government and non-governmental agencies must do all it takes to remedy the problems of shortage of resources.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Hemostasis / drug effects. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Hemorrhage / drug therapy. Hemorrhage / etiology. Humans. Karnofsky Performance Status. Middle Aged. Neoplasm Staging. Nigeria


11. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1145-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
  • OBJECTIVE: To evaluate the risk of pelvic recurrence (PVR) in high-risk pathologic Stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone.
  • METHODS: Between 1992 and 1998, 43 high-risk endometrial cancer patients received adjuvant chemotherapy.
  • No patients received preoperative radiation therapy (RT).
  • All patients received 4-6 cycles of chemotherapy as the sole adjuvant therapy, consisting primarily of cisplatin and doxorubicin.
  • Recurrent disease sites were divided into pelvic (vaginal, nonvaginal) and extrapelvic (para-aortic, upper abdomen, liver, and extra-abdominal).
  • Of the 17 women who developed a PVR, 8 relapsed in the vagina, 3 in the nonvaginal pelvis, and 6 in both.
  • The 3-year vaginal and nonvaginal PVR rates were 37.8% and 26%, respectively.
  • The most significant factor correlated with vaginal PVR was CI (p = 0.0007).
  • Nine of the 29 relapsed patients (31%) developed PVR as their only (6) or first site (3) of recurrence.
  • CONCLUSIONS: PVR is common in high-risk pathologic Stage I-IV endometrial cancer patients after adjuvant chemotherapy alone.
  • These results support the continued use of locoregional RT in patients undergoing adjuvant chemotherapy.
  • Further studies are needed to test the addition of chemotherapy to locoregional RT.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Endometrial Neoplasms / drug therapy. Pelvic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / prevention & control. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Chicago / epidemiology. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma, Papillary / epidemiology. Cystadenocarcinoma, Papillary / prevention & control. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Risk. Treatment Outcome. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / prevention & control. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483323.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Novoa Vargas A, Grados García C, Bustillos de Cima R, Malagón Millán B: [Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review]. Ginecol Obstet Mex; 2005 Dec;73(12):666-73
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review].
  • [Transliterated title] Cáncer de vagina en una mujer joven expuesta a dietilestilbestrol: caso clínico y revisión de la bibliografía.
  • We analyzed a 20 year-old patient case exposed in utero to diethylstilbestrol, as probably predisposed factor in vaginal cancer.
  • The histopathological report of the incisional biopsy was clear cell vaginal adenocarcinoma, stage III, widespread to the pelvic wall, with metastasis to regional lymph nodes, and lack of distant metastasis.
  • We decided surgical management: protocolized laparotomy, peritoneal washing, retroperitoneal node biopsies and a radical hysterectomy, Piver III, with two thirds parts of vagina.
  • By poor prognosis we decided to offer an adjuvant management, with systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Prenatal Exposure Delayed Effects. Vaginal Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymphatic Metastasis. Pregnancy. Prognosis. Radiography, Abdominal. Time Factors. Tomography, X-Ray Computed. Vagina / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583845.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


13. Frank SJ, Deavers MT, Jhingran A, Bodurka DC, Eifel PJ: Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol; 2007 May;105(2):470-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure.
  • OBJECTIVE: Primary non-diethylstilbestrol (DES)-associated adenocarcinoma of the vagina (NDAV) is a rare entity that has not been well described.
  • METHODS: The tumors of all patients treated with definitive radiation therapy for NDAV between 1970 and 2000 were centrally reviewed.
  • Data regarding patient, tumor, and treatment characteristics were abstracted from the hospital records of each patient.
  • Survival rates were calculated and outcomes of patients with NDAV were compared with those of patients with squamous cell carcinoma (SCC) of the vagina treated similarly over the same period.
  • Twenty patients (77%) were treated with external-beam radiation therapy (EBRT) followed by brachytherapy, and six patients (23%) were treated with EBRT alone.
  • At 5 years, 39% of patients with NDAV and 15% with SCC had developed distant metastasis (p<0.01).
  • Patients with this disease have significantly worse outcomes than do patients with SCC, and chemotherapy or novel systemic biologic agents may be needed to achieve higher cure rates.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Diethylstilbestrol / adverse effects. Vaginal Neoplasms / etiology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292459.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


14. Li SM, Zhang WH, Wu LY, Zhang R, Chen L: [Primary adenocarcinoma of vagina--attaching 24 cases clinical analysis]. Ai Zheng; 2002 Jan;21(1):83-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of vagina--attaching 24 cases clinical analysis].
  • BACKGROUND & OBJECTIVES: The incidence of primary vaginal adenocarcinoma was lower and its treatment was difficult and its prognosis was worse.
  • This study was designed to explore the clinical characters, treatment, prognosis of primary vaginal adenocarcinoma in this paper as the incidence of primary vaginal adenocarcinoma was lower, its treatment was difficult and its prognosis was worse.
  • RESULTS: The main clinical symptoms were vaginal bleeding and discharge.
  • Two patients were concurrently received chemotherapy and irradiation, Eight patients were received chemotherapy as the tumor was not control and recurrent or metastatic.
  • The survival mean time of patients with stage I and stage II was 60.3 months obviously much longer than 14.8 months of patients with stage III and stage IV, and they were significantly statistical difference (P < 0.01).
  • But the survival mean time of patients more than 40 years and less than or equal to 40 years was not significantly statistical difference.
  • Eight patients had local recurrence, which is the main reason of failure treatment.
  • CONCLUSIONS: Primary vaginal adenocarcinomas should mainly be adopted combined treatment depending on radiotherapy, but the prognosis was worse, the stage was the important factors affecting on the prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500405.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Nagarsheth NP, Harrison M, Kalir T, Rahaman J: Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer; 2006 May-Jun;16(3):1458-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma.
  • Malignant pericardial effusion with cardiac tamponade is a rare manifestation of metastatic gynecological cancer.
  • A 35-year-old female was diagnosed with clear cell adenocarcinoma of the vagina.
  • Four years after partial vaginectomy, she developed regional recurrence and was treated with surgical excision followed by platinum-based chemotherapy and radiation therapy.
  • Six years later, the patient was diagnosed with lung metastases and received a combination adriamycin and platinum-based chemotherapy.
  • Shortly after completing treatment, she presented with weakness and was found to be hypotensive on physical exam.
  • Computed tomography scan confirmed a pericardial effusion with evidence of bilateral heart failure.
  • She underwent an emergent pericardiocentesis and eventual pericardial window procedure.
  • Metastatic adenocarcinoma of the vagina can present with malignant pericardial effusion with cardiac tamponade.
  • Therefore, gynecologists and gynecological oncologists need to be familiar with the diagnosis and management of this disease process.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Cardiac Tamponade / etiology. Pericardial Effusion / etiology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Humans. Pericardiocentesis / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803549.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


16. Nasu K, Kai K, Matsumoto H, Mori C, Takai N, Narahara H: Primary mucinous adenocarcinoma of the vagina. Eur J Gynaecol Oncol; 2010;31(6):679-81
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the vagina.
  • PURPOSE: Primary mucinous adenocarcinoma of the vagina is a rare disease which is characterized by aggressiveness and poor prognosis because of its rapid growth and recurrence, its frequent distant metastases, and its relative resistance to conventional treatment modalities including surgery, radiotherapy, and chemotherapy.
  • We report a case of advanced stage primary mucinous adenocarcinoma of the vagina that showed a highly aggressive course and resistance to combination chemotherapy with paclitaxel and carboplatin.
  • CASE: A 46-year-old multigravid Japanese woman was admitted to our hospital to be treated for Stage IVb primary mucinous adenocarcinoma of the vagina.
  • She was treated by two courses of neoadjuvant chemotherapy with tri-weekly paclitaxel and carboplatin, which were not effective.
  • However, the disease progressed rapidly and the patient died five months after the initial treatment.
  • CONCLUSION: Because of its rarity, little is known about the behavior of primary mucinous adenocarcinoma of the vagina.
  • Additional data about patients with this rare tumor should be collected and analyzed in an attempt to elucidate its prognostic factors, characteristics, optimal treatment, and outcome.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Vagina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319516.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


17. Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R: Primary carcinoma of the vagina. J BUON; 2010 Apr-Jun;15(2):241-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the vagina.
  • In this paper we reviewed the risk factors for primary carcinoma of the vagina (PCV), diagnostic and therapeutic modalities, and principles leading to rational decision-making in the individualized management of vaginal carcinoma patients.
  • Histopathologically, most common are squamous cell carcinoma (80-90%) and adenocarcinoma (4-10%).
  • The leading risk factor for vaginal intraepithelial neoplasia (VAIN) and subsequent squamous cell vaginal carcinoma is long-lasting infection with human papillomavirus (HPV) type 16.
  • Prognosis of the disease depends on several factors, the most important of which are age, histologic type, and tumor stage.
  • Due to its being a rare entity, there are still controversies as to the most optimal treatment.
  • Individualized treatment approaches have been increasingly used.
  • In most centres, standard treatment for this cancer is radiotherapy.
  • Some reports have shown that surgery might also be an option, while in some centres radiation is supplemented by cisplatin-based chemotherapy.
  • The supposed advantage of radiotherapy is the preservation of the anatomy and function of the vagina.
  • We believe that there are certain psychologic benefits with the preservation of the vagina, regardless of its function.
  • However, preservation of the vaginal function after treatment of invasive vaginal cancer is a rare phenomenon, both in the literature and from our own experience.
  • [MeSH-major] Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658716.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 45
  •  go-up   go-down


18. Ceccaroni M, Paglia A, Ruffo G, Scioscia M, Bruni F, Pesci A, Minelli L: Symptomatic vaginal bleeding in a postmenopausal woman revealing colon adenocarcinoma metastasizing exclusively to the vagina. J Minim Invasive Gynecol; 2010 Nov-Dec;17(6):779-81
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic vaginal bleeding in a postmenopausal woman revealing colon adenocarcinoma metastasizing exclusively to the vagina.
  • Vaginal carcinomas are rare entities, accounting for 2% of all malignant cancers of the female genital tract, and the vast majority are metastatic.
  • Adenocarcinoma of the colon metastasizing to the vagina is extremely rare, only 5 cases have been reported.
  • We present the case of a woman who experienced vaginal bleeding as an isolated symptom of vaginal metastasis of colorectal adenocarcinoma.
  • Vaginal localization of metastasis from colorectal cancer significantly worsens the survival prognosis, and a standard treatment has not yet been proposed.
  • Potential mechanisms of spread of colorectal cancer to the vagina and therapeutic approaches are discussed.
  • In this case, treatment included surgery and chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Hemorrhage / etiology. Vaginal Neoplasms / complications. Vaginal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20955988.001).
  • [ISSN] 1553-4669
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sinha B, Stehman F, Schilder J, Clark L, Cardenes H: Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer; 2009 May;19(4):686-93
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indiana University experience in the management of vaginal cancer.
  • PURPOSE: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate.
  • MATERIALS AND METHODS: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities.
  • Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients).
  • RESULTS: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months).
  • CONCLUSIONS: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival.
  • Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated.
  • Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Vaginal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509572.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Batashki I, Amaliev I, Markova D, Amaliev G, Milchev N: [Ovarian cancer with metastatic lesion in the vagina (foetus papiraceus)]. Akush Ginekol (Sofiia); 2009;48(3):49-51
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer with metastatic lesion in the vagina (foetus papiraceus)].
  • Ovarian cancer spreads primarily by intraperitoneal implantation of exfoliated cancer cells, by lymphatic dissemination, and by haematogenous spread.
  • Very rarely it metastasizes to cervix, vulva and vagina; this type of metastases present a diagnostic challenge to the gynecologist and pathologist.
  • We present a case of ovarian cancer with initial clinical manifestation-lesion of the vagina.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / secondary
  • [MeSH-minor] Drug Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198766.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


21. Matsuo K, Chi DS, Eno ML, Im DD, Rosenshein NB: Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases. Gynecol Obstet Invest; 2009;68(4):276-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases.
  • BACKGROUND: Rectovaginal fistula in long-standing Crohn's disease is possibly associated with malignant transformation to mucinous adenocarcinoma of the vagina.
  • However, there have been no previously reported cases documenting vulvar cancer in association with rectovaginal fistula in Crohn's disease.
  • We report 2 cases of vulvar mucinous adenocarcinoma associated with Crohn's disease.
  • CASE 1: A 48-year-old woman, with a 30-year history of Crohn's disease including a rectovaginal fistula, developed persistent pyoderma gangrenosum.
  • Further workup revealed metastatic vulvar mucinous adenocarcinoma.
  • Biopsy showed mucinous adenocarcinoma.
  • CONCLUSION: Vulvar lesions or symptoms in the setting of rectovaginal fistula in Crohn's disease are an important clinical feature and the possible development of vulvar cancer should be considered.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Crohn Disease / complications. Rectovaginal Fistula / complications. Vulvar Neoplasms / etiology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Middle Aged. Organoplatinum Compounds / administration & dosage. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19828998.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Goker BO, Bese T, Ilvan S, Yilmaz E, Demirkiran F: A case with multiple gynecological malignancies. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):372-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with cervical non-Hodgkin lymphoma was treated with chemotherapy.
  • Fourteen months after the diagnosis of the lymphoma, an endometrial adenocarcinoma was detected as a secondary malignant tumor.
  • Approximately 7 years after the diagnosis of endometrial cancer, vaginal invasive squamous cell carcinoma was diagnosed as the third primary malignancy, and a second-line palliative radiotherapy was applied.
  • Seven months after the last radiotherapy, postradiational sarcoma in the vagina was diagnosed.
  • Congenital and acquired immune system disorders, viral oncogenes, and various human leukocyte antigen (HLA) types were investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Uterine Cervical Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823128.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Temkin SM, Hellman M, Lee YC, Abulafia O: Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases. J Low Genit Tract Dis; 2007 Apr;11(2):118-21
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases.
  • OBJECTIVE: Endometrial cancer generally carries a good prognosis.
  • One half of these recurrences are confined to the vagina.
  • Whereas pelvic recurrence is most common in patients who do not receive postoperative adjuvant radiation therapy, distant metastases predominate among patients who received postoperative radiation therapy.
  • Surgical resection of disease may be possible, therapeutic and even curative, in select patients with isolated cancer recurrence.
  • CASE 1: A 63-year-old patient presented 7 years after treatment of endometrial cancer with a vulvar lesion and groin mass.
  • The lesions were successfully resected and confirmed to be recurrent endometrial cancer.
  • Adjuvant radiation and chemotherapy were prescribed leading to a complete clinical response.
  • CASE 2: An 83-year-old patient with a history of a hysterectomy for endometrial cancer and radiation therapy for a vaginal vault recurrence presented with an exophytic labial mass.
  • After radical wide excision of her vulvar mass and bilateral groin dissection, final pathology revealed that the mass was consistent with recurrent endometrial cancer.
  • This patient remains without evidence of disease 18 months after treatment of disease recurrence.
  • CONCLUSIONS: Uncommon sites of recurrence of endometrial cancer may include the vulva.
  • These rare metastases may be amenable to surgical resection with adjuvant therapy as indicated.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Gynecologic Surgical Procedures. Vulvar Neoplasms / surgery
  • [MeSH-minor] Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415118.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Zarbo G, Caruso G, Zammitti M, Caruso S, Zarbo R: The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol; 2000;21(1):86-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of tamoxifen therapy on the endometrium.
  • From January 1992 to December 1998, 219 women (aged between 30 and 81 yrs; average 55 years) affected by breast cancer were treated.
  • These women in addition to the usual adjuvant therapy, were treated with TAM 20 mg/day, for a period between 24 and 72 months (average 40).
  • In 8 fertile patients ovarian activity was suppressed with GnRh analogue therapy and one patient underwent attinic castration.
  • Before performing TAM therapy, a hysteroscopic exam was done and patients were followed-up with an annual check-up.
  • After two years, 31 women (26.9%) complained of endometrial alterations (hyperplasia, polyps and endometrial cancer).
  • One women only after 6 years of follow-up, had metrorrhagia; an endometrial adenocarcinoma was found.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endometrium / drug effects. Endometrium / pathology. Female. Follow-Up Studies. Humans. Hysteroscopy. Incidence. Middle Aged. Vagina / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10726629.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


25. McGonigle KF, Smith DD, Marx HF, Morgan RJ, Vasilev SA, Roy S, Wong PT, Simpson JF, Wilczynski SP: Uterine effects of tamoxifen: a prospective study. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):814-20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the study was to evaluate tamoxifen-associated changes in the vagina and uterus in postmenopausal breast cancer patients.
  • Between June 1994 and December 1998, 45 patients enrolled in a prospective study before commencing tamoxifen therapy.
  • Transvaginal ultrasonography, vaginal maturation indexes (VMI), and endometrial biopsy were performed at baseline and repeated at 6 months (n= 42), 1 year (n= 39), 2 years (n= 32), 3 years (n= 26), 4 years (n= 19), and 5 years (n= 15).
  • No cases of endometrial hyperplasia or adenocarcinoma were detected.
  • Tamoxifen exerts a weak estrogenic effect on the vagina and uterus in highly prescreened postmenopausal women without preexisting endometrial pathology.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Postmenopause. Tamoxifen / therapeutic use. Uterus / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endometrium / drug effects. Female. Humans. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681767.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


26. Kruse K, Lauver D, Hanson K: Clinical implications of DES. Nurse Pract; 2003 Jul;28(7 Pt 1):26-32,35, table of contents; quiz 35-7
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of DES.
  • Once prescribed to pregnant women to prevent risk of spontaneous abortion, diethylstilbestrol (DES) is now associated with an increased risk of breast cancer, clear cell adenocarcinoma (CCA) of the vagina and cervix, and reproductive anomalies.
  • This article will summarize the potential long-term health implications of DES, the role of nurse practitioners in identifying exposed individuals, and proper clinical management.
  • [MeSH-major] Abnormalities, Drug-Induced / etiology. Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Pregnancy Complications / chemically induced. Prenatal Exposure Delayed Effects. Urogenital Neoplasms / chemically induced
  • [MeSH-minor] Abortion, Spontaneous / drug therapy. Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Adolescent. Adult. Female. Humans. Infertility / chemically induced. Male. Medical History Taking / methods. Patient Education as Topic / methods. Pregnancy

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12861092.001).
  • [ISSN] 0361-1817
  • [Journal-full-title] The Nurse practitioner
  • [ISO-abbreviation] Nurse Pract
  • [Language] eng
  • [Grant] United States / PHS HHS / / 00T00225101D
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 19
  •  go-up   go-down


27. Horejsí J, Rob L: [Malignant tumors of the female genitalia in childhood--yesterday, today and tomorrow]. Cas Lek Cesk; 2003 Feb;142(2):84-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors of the external genital are very rare (sarcomas of the soft tissues).
  • Malignancies of vagina are represented by the embryogenic rabdomyosarcoma, yolk sack tumor and tumor of pale cells or vaginal adenocarcinoma.
  • Cytostatics are used as the basic therapy and only later the less radical surgery is recommended.
  • Vaginal bleeding of the premenarcheal girl is an early symptom and requires immediate examination, including vaginoscopy.
  • They differ in types from those of adults: Epithelial tumors (carcinomas) do not occur in childhood, germinal and gonadal stromal tumors are typical in this age.
  • Beside ovarectomy, also lymphadenectomy at the affected side is performed and the treatment proceeds with chemotherapy.
  • To protect gonad from the adverse effects of oncological treatment, pharmacologically induced regression to premenarcheal stadium has been tested.
  • Complex treatment of gonadal malignancies in childhood in future will be aimed not only at the lifesaving but also at the preservation of the highest possible quality of life, including the motherhood.
  • [MeSH-minor] Adolescent. Child. Female. Humans. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12698534.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 8
  •  go-up   go-down


28. Strauss HG, Kuhnt T, Laban C, Puschmann D, Pigorsch S, Dunst J, Koelbl H, Haensgen G: Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol; 2002 Jul;178(7):378-85
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
  • BACKGROUND: In 1999, five randomized studies demonstrated that chemoradiation with cisplatin and low-dose rate (LDR) brachytherapy has a benefit in locally advanced cervical cancer and for surgically treated patients in high-risk situations.
  • We evaluated the safety and efficacy of concomitant chemoradiation with cisplatin and high-dose rate (HDR) brachytherapy in patients with cervical cancer.
  • PATIENTS AND METHODS: 27 patients were included in our phase-II trial: 13 locally advanced cases (group A) and 14 adjuvant-therapy patients in high-risk situations (group B).
  • A definitive radiotherapy was performed with 25 fractions of external beam therapy (1.8 Gy per fraction/middle shielded after eleven fractions).
  • Brachytherapy was delivered at HDR schedules with 7 Gy in point A per fraction (total dose 35 Gy) in FIGO Stages IIB-IIIB.
  • The total dose of external and brachytherapy was 70 Gy in point A and 52-54 Gy in point B.
  • Adjuvant radiotherapy was performed with external beam radiotherapy of the pelvis with 1.8 Gy single-dose up to 50.4 Gy.
  • Brachytherapy was delivered at HDR schedules with two fractions of 5 Gy only in patients with tumor-positive margins or tumor involvement of the upper vagina.
  • The chemotherapeutic treatment schedule provided six courses of cisplatin 40 mg/m2 weekly recommended in the randomized studies GOG-120 and -123.
  • RESULTS: A total of 18/27 patients (66.7%) completed all six courses of chemotherapy.
  • Discontinuation of radiotherapy due to therapy-related morbidity was not necessary in the whole study group.
  • 12/13 patients (92.3%) with IIB-IVA cervical cancer showed a complete response (CR).
  • CONCLUSION: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly x 6 using HDR brachytherapy represents a promising treatment of cervical cancer with an acceptable toxicity.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12163992.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Myriokefalitaki E, Iavazzo C, Vorgias G, Akrivos T: A two eterochronous primary gynaecological malignancies of different origin. Bratisl Lek Listy; 2009;110(11):726-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 65-year-old para-2, white obese female, presented in our department 4 years ago, due to a single event of vaginal spotting.
  • Curettage revealed an endometrial cancer.
  • Histology showed an endometrioid adenocarcinoma of endometrium stage Ib, moderately differentiated.
  • No additional therapy was given.
  • Although, recurrence on vaginal cuff was possible, the biopsies of anterior vaginal wall showed a poorly differentiated squamous cell carcinoma of the vagina.
  • The patient was classified as stage II vaginal carcinoma and underwent complete radiotherapy and chemotherapy.
  • CONCLUSION: This case indicates that female genital carcinomas of different histological origins may occur with minimal time-interval, even in the absence of known predisposing factors like previous chemo-radiotherapy, HPV infection or diethylstilbestrol exposure.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Squamous Cell / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Vaginal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120445.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


30. Uzan C, Vincens E, Balleyguier C, Gouy S, Pautier P, Duvillard P, Haie-Meder C, Morice P: Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy. Int J Gynecol Cancer; 2010 Apr;20(3):379-84
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy.
  • OBJECTIVE: Standard treatment of stage IB2/II cervical carcinoma is chemoradiation therapy.
  • The place of surgery after this treatment is debated, except when there is suspicion of residual disease.
  • (1) stage IB2/II cervical cancer, (2) external radiotherapy (45 Gy) with concomitant chemotherapy followed by uterovaginal brachytherapy (15 Gy), (3) magnetic resonance imaging performed between 3 and 8 weeks after brachytherapy, and (4) completion surgery with incomplete resection of pelvic disease.
  • The locations of the incomplete resection were (some patients had several locations) the parametrium (n = 4), lateral limit of the cervix (n = 4), anterior (n = 2), posterior (n = 3), and vagina (n = 2).
  • One patient had received chemotherapy for metastatic para-aortic nodes.
  • CONCLUSIONS: The prognosis is poor when resection is incomplete after chemoradiation therapy in advanced-stage cervical cancer, and further surgery does not seem to improve this outcome.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / therapy. Hysterectomy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual / pathology. Neoplasm, Residual / therapy. Para-Aortic Bodies / pathology. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375801.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ajit D, Gavas S, Jagtap S, Chinoy RF: Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy. Acta Cytol; 2009 Jul-Aug;53(4):383-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy.
  • OBJECTIVE: To evaluate the effect of tamoxifen on cervicovaginal epithelium, identify tamoxifen-related changes that mimic cancer and detennine the morphologic features differentiating the 2 changes.
  • STUDY DESIGN: Cervicovaginal smears from 153 conventionally treated primary breast cancer patients presenting with gynecologic symptoms were studied.
  • Of the 6 cases reported as adenocarcinoma, 3 were histologically confirmed, and the others were false positives.
  • Tamoxifen-associated cellular changes can mimic morphologic features of cancer.
  • To avoid diagnostic errors, cervicovaginal smears should be repeated after discontinuing tamoxifen treatment.
  • Regular follow-up with cervicovaginal smears from patients on tamoxifen treatment is recommended.
  • [MeSH-major] Cervix Uteri / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged


32. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • At presentation, the patients had either vaginal bleeding or pelvic pain.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen ().
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Mahdavi A, Shamshirsaz AA, Peiretti M, Zakashansky K, Idrees MT, Nezhat F: Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review. J Minim Invasive Gynecol; 2006 May-Jun;13(3):237-41
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review.
  • Vaginal clear cell adenocarcinoma arising from pelvic endometriosis has not been reported in the literature.
  • We report a case of a 50-year-old woman with stage I clear cell adenocarcinoma of the vagina who was found to have endometriosis adjacent to the vaginal tumor.
  • She was treated with neoadjuvant chemoradiation, laparoscopically assisted radical vaginal hysterectomy, radical upper vaginectomy, and pelvic lymphadenectomy followed by combination chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Endometriosis / complications. Endometriosis / surgery. Vaginal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Laparoscopy. Middle Aged. Neoplasm Staging. Pelvis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698533.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


34. Swan SH: Intrauterine exposure to diethylstilbestrol: long-term effects in humans. APMIS; 2000 Dec;108(12):793-804
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DES is the most carefully scrutinized EDC and its history provides valuable insights into the current evaluation of less well-studied EDCs.
  • This review summarizes the health effects of prenatal exposure to diethylstilbestrol (DES) and emphasizes the role of DES as the first endocrine disrupting chemical (EDC).
  • Vaginal clear cell adenocarcinoma (CCAC), the most severe consequence of prenatal exposure to DES, affected only 0.1% of exposed females, while the far more prevalent teratogenic and reproductive effects of DES were only discovered when DES daughter were screened for CCAC.
  • Initial studies, conducted before most DES daughters had tried to conceive, examined vaginal cancer and vaginal, cervical and uterine abnormalities.
  • Subsequently, several controlled studies demonstrated the increased risk of adverse reproductive outcomes in DES daughters.
  • While most DES daughters can eventually experience a live birth, this is less likely in women with genital tract abnormalities, in whom there is a two-thirds chance that each pregnancy will be unsuccessful.
  • In DES sons, who have been far less studied, results suggest male reproductive toxicity, but are less consistent.
  • The importance of dose and gestational age at initial exposure are discussed, and the implications of DES findings for the evaluation of risks from current EDCs emphasized.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Pregnancy Complications / drug therapy. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Adenocarcinoma, Clear Cell / chemically induced. Administration, Intravaginal. Cervix Uteri / abnormalities. Female. Follow-Up Studies. Gestational Age. Humans. Infant, Newborn. Infant, Newborn, Diseases / chemically induced. Infant, Newborn, Diseases / epidemiology. Male. Pregnancy. Risk. Teratoma / chemically induced. Testicular Neoplasms / chemically induced. United States / epidemiology. Uterus / abnormalities. Vagina / abnormalities. Vaginal Diseases / chemically induced. Vaginal Diseases / epidemiology. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11252812.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 75
  •  go-up   go-down


35. Cao L, Li X, Zhang Y, Li X, Wang Q: [Clinical features and prognosis of cervical cancer in young women]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug;35(8):875-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of cervical cancer in young women].
  • OBJECTIVE: To investigate the prevalence, etiology, clinical presentation and pathological features, treatment and prognosis of cervical cancer in young women.
  • METHODS: Clinical data of 132 young women with cervical cancer were reviewed.
  • RESULTS: Positive rate of human papillomavirus 18 was high in young women with cervical cancer.
  • The primary clinical presentation of young patients with cervical cancer was contact bleeding of vagina, and the signs were out-expanding of cervical mass.
  • The percentage of adenocarcinoma increased.
  • The main treatment for cervical cancer was surgery.
  • CONCLUSION: Contact bleeding is a significant symptom in young women with cervical cancer.
  • Surgery is first considered in the treatment.
  • Preoperative neoadjuvant chemotherapy can be used in patients with locally advanced and late stage cervical cancer.
  • [MeSH-major] Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818083.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


37. Herbst AL: Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES). Gynecol Oncol; 2000 Feb;76(2):147-56
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES).
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Breast Neoplasms / chemically induced. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Genital Neoplasms, Female / chemically induced. Neoplasms, Hormone-Dependent / chemically induced
  • [MeSH-minor] Contraceptives, Oral, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Female. Hormone Replacement Therapy / adverse effects. Humans. Neoplasm Staging. Pregnancy. Prenatal Exposure Delayed Effects. Prognosis. Uterus / drug effects. Uterus / embryology. Vagina / drug effects. Vagina / embryology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10637063.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62912
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Contraceptives, Oral, Hormonal; 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 35
  •  go-up   go-down






Advertisement